Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2006 2
2007 1
2008 6
2009 11
2010 8
2011 5
2012 16
2013 15
2014 9
2015 10
2016 12
2017 13
2018 12
2019 8
2020 8
2021 8
2022 16
2023 16
2024 9
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Results by year

Filters applied: . Clear all
Page 1
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D'Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horowitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Del Valle DM, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK. Galsky MD, et al. Among authors: yu m. Nat Med. 2023 Nov;29(11):2825-2834. doi: 10.1038/s41591-023-02568-1. Epub 2023 Oct 2. Nat Med. 2023. PMID: 37783966 Free PMC article. Clinical Trial.
Morphologic Spectrum of HPV-associated Sinonasal Carcinomas.
Abi-Saab T, Lozar T, Chen Y, Tannenbaum AP, Geye H, Yu M, Weisman P, Harari PM, Kimple RJ, Lambert PF, Lloyd RV, Hu R. Abi-Saab T, et al. Among authors: yu m. Head Neck Pathol. 2024 Aug 5;18(1):67. doi: 10.1007/s12105-024-01670-1. Head Neck Pathol. 2024. PMID: 39101976
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
Zhao SG, Sperger JM, Schehr JL, McKay RR, Emamekhoo H, Singh A, Schultz ZD, Bade RM, Stahlfeld CN, Gilsdorf CS, Hernandez CI, Wolfe SK, Mayberry RD, Krause HM, Bootsma M, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Kyriakopoulos CE, Kosoff D, Wei XX, Floberg J, Sethakorn N, Sharifi M, Harari PM, Huang W, Beltran H, Choueiri TK, Scher HI, Rathkopf DE, Halabi S, Armstrong AJ, Beebe DJ, Yu M, Sundling KE, Taplin ME, Lang JM. Zhao SG, et al. Among authors: yu m. J Clin Invest. 2022 Nov 1;132(21):e161858. doi: 10.1172/JCI161858. J Clin Invest. 2022. PMID: 36317634 Free PMC article.
High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes.
Sharifi MN, Sperger JM, Taylor AK, Tippins KE, Reese SR, Carreno V, Kaufmann KR, Chang AH, Nunamaker LA, Linebarger C, Mora-Rodriguez L, Schehr JL, Krause HM, Helzer KT, Bootsma ML, Blitzer GC, Floberg JM, Kyriakopoulos CE, Emamekhoo H, Heath EI, Wells M, Tagawa ST, Sjöström M, Choudhury AD, Yu M, Armstrong AJ, Rathkopf DE, Beltran H, Nelson PS, Feng FY, Dehm SM, Kosoff D, Wei XX, McKay RR, Zhao SG, Lang JM. Sharifi MN, et al. Among authors: yu m. Cancer Discov. 2025 Apr 1:OF1-OF19. doi: 10.1158/2159-8290.CD-24-1509. Online ahead of print. Cancer Discov. 2025. PMID: 40167119
High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes.
Sharifi MN, Sperger JM, Taylor AK, Tippins KE, Reese SR, Carreno V, Kaufmann KR, Chang AH, Nunamaker LA, Linebarger C, Mora-Rodriguez L, Schehr JL, Krause HM, Helzer KT, Bootsma ML, Blitzer GC, Floberg JM, Kyriakopoulos CE, Emamekhoo H, Heath EI, Wells M, Tagawa ST, Sjöström M, Choudhury AD, Yu M, Armstrong AJ, Rathkopf DE, Beltran H, Nelson PS, Feng FY, Dehm SM, Kosoff D, Wei XX, McKay RR, Zhao SG, Lang JM. Sharifi MN, et al. Among authors: yu m. Cancer Discov. 2025 Feb 6. doi: 10.1158/2159-8290.CD-24-1509. Online ahead of print. Cancer Discov. 2025. PMID: 39912912
Which test for crossing survival curves? A user's guideline.
Dormuth I, Liu T, Xu J, Yu M, Pauly M, Ditzhaus M. Dormuth I, et al. Among authors: yu m. BMC Med Res Methodol. 2022 Jan 30;22(1):34. doi: 10.1186/s12874-022-01520-0. BMC Med Res Methodol. 2022. PMID: 35094686 Free PMC article. Review.
From Bench to Bedside: A Team's Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.
Crossman BE, Harmon RL, Kostecki KL, McDaniel NK, Iida M, Corday LW, Glitchev CE, Crow MT, Harris MA, Lin CY, Adams JM, Longhurst CA, Nickel KP, Ong IM, Alexandridis RA, Yu M, Yang DT, Hu R, Morris ZS, Hartig GK, Glazer TA, Ramisetty S, Kulkarni P, Salgia R, Kimple RJ, Bruce JY, Harari PM, Wheeler DL. Crossman BE, et al. Among authors: yu m. J Clin Med. 2024 Oct 10;13(20):6036. doi: 10.3390/jcm13206036. J Clin Med. 2024. PMID: 39457986 Free PMC article. Review.
167 results